II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
KEY PUBLICA TIONS OF CANCER OF ORAL CAVITY - PART II
Chairpersons :
Rajesh Valand, ENT Surgeon, Mumbai, Shekhar Kesari, Radiation Oncologist, Patna, Bachi Hathiram, ENT Specialist, Mumbai
Speaker :
Pranav Chadha